World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
96
Citations
52371
World Ranking
9484
National Ranking
4893

Rebecca Gelman publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Rebecca Gelman sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 308 publications — 18th percentile

18% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Rebecca Gelman D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Rebecca Gelman sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 96 D-Index — 53rd percentile

53% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Rebecca Gelman is affiliated with Harvard University in the United States. Their research primarily focuses on medicine and biochemistry, genetics, and molecular biology, with particular attention to oncology, pulmonary and respiratory medicine, and genetics. The work also touches on cancer research and surgery.

The scientist's research topics encompass a range of areas related to cancer and treatment, including:

  • BRCA gene mutations in cancer
  • Cancer treatment and pharmacology
  • Brain metastases and treatment
  • HER2/EGFR in cancer research
  • PARP inhibition in cancer therapy
  • Advanced breast cancer therapies
  • Breast cancer treatment studies

Recent publications authored or coauthored by Rebecca Gelman include:

  • "Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100,800 women from 86 randomised trials," 2023, The Lancet
  • "Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases," 2020, Breast Cancer Research
  • "The Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In Situ in Patients with Intraductal Papilloma without Atypia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 034)," 2020, Annals of Surgical Oncology
  • "Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations," 2021, Breast Cancer Research and Treatment
  • "Pretest Video Education Versus Genetic Counseling for Patients With Prostate Cancer: ProGen, A Multisite Randomized Controlled Trial," 2023, JCO Oncology Practice

Frequent coauthors collaborating with Gelman include:

  • Eric P. Winer
  • Michelle Weitz
  • Judy E. Garber
  • Nancy U. Lin
  • Huma Q. Rana

Their work has been published in venues such as UNC Libraries, The Lancet, JCO Oncology Practice, Breast Cancer Research, and Annals of Surgical Oncology. Gelman's contributions are marked by multiple papers across these journals, with UNC Libraries featuring two publications.

Best Publications

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

    C Focan;SM Steinberg;M Blichert-Toft;JF Forbes

  • Molecular Definition of Breast Tumor Heterogeneity

    Michail Shipitsin;Lauren L. Campbell;Pedram Argani;Stanislawa Weremowicz

  • Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

    Daniel P. Silver;Andrea L. Richardson;Aron C. Eklund;Zhigang C. Wang

  • Control of Viremia and Prevention of Clinical AIDS in Rhesus Monkeys by Cytokine-Augmented DNA Vaccination

    Dan H. Barouch;Sampa Santra;Jörn E. Schmitz;Marcelo J. Kuroda

  • Intracranial germ-cell tumors: natural history and pathogenesis.

    Mark T. Jennings;Rebecca Gelman;Fred Hochberg

  • Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

    Johanna C. Bendell;Susan M. Domchek;Harold J. Burstein M.D.;Lyndsay Harris

  • Lymphocyte subsets in healthy children from birth through 18 years of age : The pediatric AIDS clinical trials group P1009 study

    William T. Shearer;Howard M. Rosenblatt;Rebecca S. Gelman;Rebecca Oyomopito

  • Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer.

    Asa J. Nixon;Donna Neuberg;Daniel F. Hayes;Rebecca Gelman

  • Outcome at 8 Years After Breast-Conserving Surgery and Radiation Therapy for Invasive Breast Cancer: Influence of Margin Status and Systemic Therapy on Local Recurrence

    Catherine C. Park;Michihide Mitsumori;Asa Nixon;Abram Recht

  • Network modeling links breast cancer susceptibility and centrosome dysfunction.

    Miguel Angel Pujana;Jing Dong J Han;Lea M. Starita;Kristen N. Stevens

  • The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast‐conserving surgery and radiation therapy

    Stuart J. Schnitt;Anthony Abner;Rebecca Gelman;James L. Connolly

  • The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer.

    Recht A;Come Se;Henderson Ic;Gelman Rs

  • Regulation of In Situ to Invasive Breast Carcinoma Transition

    Min Qi Hu;Jun Yao;Danielle K. Carroll;Stanislawa Weremowicz

  • Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria.

    Stuart J. Schnitt;James L. Connolly;Fattaneh A. Tavassoli;Robert E. Fechner

  • The presence of an extensive intraductal component following a limited excision correlates with prominent residual disease in the remainder of the breast.

    Roland Holland;James L. Connolly;Rebecca Gelman;Marcel Mravunac

  • Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.

    Nancy U. Lin;Lisa A. Carey;Minetta C. Liu;Jerry Younger

  • Clinical Activity of Trastuzumab and Vinorelbine in Women With HER2-Overexpressing Metastatic Breast Cancer

    Harold J. Burstein;Irene Kuter;Susana M. Campos;Rebecca S. Gelman

  • Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm

    Harold J. Burstein;Lyndsay N. Harris;P. Kelly Marcom;Rosemary Lambert-Falls

  • Pathologic margin involvement and the risk of recurrence in patients treated with breast-conserving therapy.

    Irene Gage;Irene Gage;Stuart J. Schnitt;Asa J. Nixon;B A Barbara Silver

Frequent Co-Authors

Jay R. Harris
Jay R. Harris Brigham and Women's Hospital
Abram Recht
Abram Recht Beth Israel Deaconess Medical Center
Stuart J. Schnitt
Stuart J. Schnitt Brigham and Women's Hospital
Eric P. Winer
Eric P. Winer Yale University
James L. Connolly
James L. Connolly Beth Israel Deaconess Medical Center
Harold J. Burstein
Harold J. Burstein Harvard University
Judy Garber
Judy Garber Harvard University
Norman L. Letvin
Norman L. Letvin Beth Israel Deaconess Medical Center
Ian E. Krop
Ian E. Krop Harvard University
Kornelia Polyak
Kornelia Polyak Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Medicine offers diverse career pathways, and online degrees now make it easier to upskill or specialize. For nurses aspiring to advanced roles in mental health, the fastest post master's pmhnp programs provide a flexible route to becoming a Psychiatric Mental Health Nurse Practitioner, allowing you to complete your studies at an accelerated pace.

Healthcare management is also in high demand. Individuals interested in leadership, policy, or hospital administration may consider competing for roles by pursuing the best online mha programs. These programs often accommodate working professionals and can be a smart option for those conscious of costs.

Financial considerations are central when choosing your education path. Understanding masters in healthcare administration cost can help you make informed decisions about tuition and return on investment.

Finally, those aiming for the highest clinical leadership should explore cheap dnp online programs, which deliver advanced nursing education at a lower cost, maximizing career potential without excessive financial burden.

Best Scientists Citing Rebecca Gelman

Trending Scientists